
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
(FDA) advisory committee members voted 16-8 in favor of a mandatory registry, a plan which was also supported by Hoffman-LaRoche and generic isotretinoin manufacturers.